X
[{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"SCIB1 Investigational New Drug (IND) application approved","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2020","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Kicks Off COVID-19 Vaccine Development","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"April 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Scancell","sponsor":"Innovate UK","pharmaFlowCategory":"D","amount":"$2.6 million","upfrontCash":"Undisclosed","newsHeadline":"Scancell Led Consortium Awarded Funding by Innovate UK to Progress Second Generation Covid-19 Vaccine Into Clinical Trials","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"Undisclosed","date":"August 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Announces Selection of COVID-19 Vaccine Candidate, SN14","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"IND Enabling","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"IND Enabling"},{"orgOrder":0,"company":"Scancell","sponsor":"University of Cape Town Lung Institute","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"First Subject Dosed in COVIDITY Phase 1 Clinical Trial In South Africa","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"October 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Scancell Announces Positive Response In COVIDITY Trial","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Scancell","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Encouraging Early Efficacy Data from Monotherapy Part Of ModiFY Phase 1\/2 Clinical Trial","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"February 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Scancell","sponsor":"PharmaJet","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Announces Clinical Results from Scancell\u2019s COVID-19 DNA Vaccine Study Exclusively Administered with Their Needle-free Precision Delivery Systems","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase I\/ Phase II","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"March 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase I\/ Phase II"},{"orgOrder":0,"company":"Scancell","sponsor":"PharmaJet","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PharmaJet Partner, Scancell, Announces Positive Data from the First Stage of its Phase 2 Trial of Advanced Melanoma DNA Vaccine delivered Needle-free","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"UNITED KINGDOM","productType":"Vaccine","productStatus":"New Molecular Entity","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"}]
Find Clinical Drug Pipeline Developments & Deals by Scancell
Filters
Companies By Therapeutic Area
Details:
ImmunoBody® vaccines are designed to induce potent cytotoxic CD8 T cell responses against multiple epitopes via a dual mechanism of action. These DNA vaccines are being used both for the treatment of cancer.
Lead Product(s):
SCIB1,Nivolumab ,Ipilimumab
Therapeutic Area: Oncology
Product Name: SCIB1
Highest Development Status: Phase II/ Phase III
Product Type: Vaccine
Recipient:
PharmaJet
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
September 28, 2023
Details:
Covidity (SCOV1 and SCOV2 vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Lead Product(s):
SCOV1,SCOV2
Therapeutic Area: Infections and Infectious Diseases
Product Name: COVIDITY
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
PharmaJet
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
March 21, 2023
Details:
Modi-1 vaccine comprises three citrullinated peptides, two derived from vimentin and one from α-enolase, peptides from two different proteins have been combined in this way to reduce the possibility of tumour escape by activating CD4 cells.
Lead Product(s):
Modi-1,Pembrolizumab
Therapeutic Area: Oncology
Product Name: Modi-1
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 21, 2023
Details:
Covidity (plasmid DNA vaccine), administered via needle-free intradermal injection, is a prophylactic DNA vaccine produces a durable immunity against the SARS-CoV-2 virus.
Lead Product(s):
Plasmid DNA Vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: COVIDITY
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 13, 2023
Details:
SCOV1 and SCOV2 are based on a modification of Scancell's ImmunoBody® DNA vaccine technology to induce high avidity T-cell immune responses against both N and S viral antigens. COVIDITY clinical trial assess safety and immunogenicity of SCOV1 and SCOV2.
Lead Product(s):
SCOV1,SCOV2
Therapeutic Area: Infections and Infectious Diseases
Product Name: Covidity
Highest Development Status: Phase I/ Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
University of Cape Town Lung Institute
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
October 05, 2021
Details:
SN14 also incorporates Scancell’s AvidiMab™ technology to further enhance this immune response demonstrating the broad potential of this platform technology to generate improved vaccines for both infectious diseases and cancer.
Lead Product(s):
SN14
Therapeutic Area: Infections and Infectious Diseases
Product Name: SN14
Highest Development Status: IND Enabling
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
December 18, 2020
Details:
The funding will be used to initiate a Phase 1 clinical trial (“COVIDITY”) during 2021. Scancell’s DNA vaccines target dendritic cells to stimulate high avidity T cells that identify and destroy diseased cells.
Lead Product(s):
Covid 19 vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Innovate UK
Deal Size: $2.6 million
Upfront Cash: Undisclosed
Deal Type: Funding
August 27, 2020
Details:
Scancell has developed DNA vaccines that target dendritic cells to stimulate high avidity T cells that survey and destroy diseased cells.
Lead Product(s):
DNA vaccine
Therapeutic Area: Infections and Infectious Diseases
Product Name: Undisclosed
Highest Development Status: IND Enabling
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
April 24, 2020
Details:
Scancell will initiate the US arm of the Phase 2 clinical trial of SCIB1 in patients with metastatic melanoma, receiving the checkpoint inhibitor pembrolizumab, using Ichor’s TriGrid® .
Lead Product(s):
SCIB1
Therapeutic Area: Oncology
Product Name: Undisclosed
Highest Development Status: Phase II
Product Type: Vaccine
Partner/Sponsor/Collaborator:
Not Applicable
Deal Size: Not Applicable
Upfront Cash: Not Applicable
Deal Type: Not Applicable
February 03, 2020